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Graphical Abstract 
 
 
 
 
 
Patient 1 2 3 4 5 
Current age 
(years) 8 11 11 6 7 
Developmenta
l delay/ID Yes Yes Yes Yes Yes 
Current 
speech 
abilities Limited language; 2 word phrases, unable to name common objects 
Limited language; 2 word phrases Babbling, some specific sounds Short 3-word phrases Can speak in sentences; language on the CELF is at ~ 4 year level 
ADD/ADHD Hyperactive and inattentive Yes Hyperactive Attention difficulties Not hyperactive, but distracted in classroom environment 
Seizures Yes – onset at 22 mos Yes – onset at 2 years Yes Yes – first at 4 mos Yes 
Seizure type / 
EEG results Generalized epilepsy; absence seizures (intractable) 
Generalized, tonic clonic seizures (intractable) 
Myoclonic, atonic drop seizures, absence, tonic, tonic-clonic (intractable) 
Myoclonic epilepsy - diagnosed at age 1.5 yo; myoclonic astatic 
Staring episodes with clonic jerks; generalized epilepsy (intractable) 
Seizure 
frequency Hundreds per day 10-15 per day 40-60 per day Daily  Daily  
Ataxia Wide-based unsteady gait with toe walking 
Broad-based gait Ataxic gait, toe walking Problems with coordination None 
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Abstract 
 Intellectual disability (ID) affects about 3% of the population and has a male gender bias. Of at least 700 genes currently linked to ID, more than 100 have been identified on the X chromosome, including KIAA2022. KIAA2022 is located on Xq13.3 and is expressed in the developing brain. The protein product of KIAA2022, X-linked Intellectual Disability Protein Related to Neurite Extension (XPN), is developmentally regulated and is involved in neuronal migration and cell adhesion. The clinical manifestations of loss-of-function KIAA2022 mutations have been described previously in fifteen males, born from unaffected carrier mothers, but few females.  Using whole exome sequencing, we identified a cohort of five unrelated female patients with de novo likely gene damaging variants in KIAA2022 and core phenotypic features of intellectual disability, developmental delay, epilepsy refractory to treatment, and impaired language, of similar severity as reported for male counterparts. This study supports KIAA2022 as a novel cause of X-linked dominant intellectual disability, and broadens the phenotype for KIAA2022 mutations. 
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Introduction 
 With the availability of whole exome sequencing (WES), our understanding of the genetic causes of neurological conditions such as intellectual disability (ID) and autism, is rapidly expanding [1-3]. As both ID and autism are more frequent in males, with a ratio of 1.3:1 for ID and 4:1 for autism, studying the X chromosome has been informative in identifying genes linked to these conditions, including KIAA2022 [4-6].  
KIAA2022 (OMIM 300524) maps to Xq13.3 and was first described by Cantagrel, et al in 2004 in two related males with severe to profound intellectual disabilities, autism, absent language development, and dysmorphic facial features [7]. Since then, sixteen more patients from nine families have been described with loss-of-function mutations in KIAA2022 and similar clinical phenotypes [8-13].  Females 
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with de novo loss of function mutations in KIAA2022 have also recently been reported to be associated with intellectual disabilities and intractable epilepsy [14].    
KIAA2022 is expressed in the developing brain. Expression of Kiaa2022, the murine ortholog, begins on E11.5, increases during embryonic development, and spreads to areas that later become the hippocampus, entorhinal and piriform cortices, and the hypothalamic ventral premammillary nucleus. Expression tapers off in adulthood [15].   
KIAA2022 encodes two protein products: the primary 1516 amino acid protein X-linked Intellectual Disability Protein Related to Neurite Extension (XPN), and an unnamed 118 amino acid protein [15].  Mechanistic insights have been gained through suppression of XPN [16]. XPN suppression leads to an increase in N-cadherin and B1-integrin levels [17]. Through regulation of neural signaling pathways, N-cadherin and B1-integrin impact not only neuronal migration and cell adhesion, but also the growth and proliferation of neurites which are critical for developing neuronal circuits [18-21].   We present five unrelated females with de novo likely damaging variants in the protein-coding region of KIAA2022, with overlapping core features of global 
This article is protected by copyright. All rights reserved.
6  
developmental delay, intellectual disabilities and medically refractory epilepsy, and expand the phenotype of KIAA2022 deficiency to females.   
Materials and Methods 
 The study population is a consecutive case series of patients referred for clinical whole exome sequencing to a clinical diagnostic laboratory.  Informed consent was obtained from all individual participants included in this study. This study was approved by the Institutional Review Board of Columbia University. Genomic DNA was extracted from whole blood from the affected children and their family members. Whole exome sequencing (WES) at GeneDx was performed on exon targets isolated by capture using the Agilent SureSelect Human All Exon V4 (50 Mb) kit or Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). The sequencing methodology and variant interpretation protocol has been previously described [22]. All variants reported were confirmed with Sanger sequencing.  The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page. 
 
Results 
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Among 2,323 females with developmental delay/intellectual disabilities who were evaluated with clinical WES, we identified six individuals with de novo predicted pathogenic variants in KIAA2022, one of whom is not included in this paper.  WES produced an average of ~9GB of sequence per sample. Mean coverage of captured regions was ~110X per sample, with >96% covered with at least 10x coverage, an average of 89% of base call quality of Q30 or greater, and an overall average mean quality score of >Q36.  All reported variants in KIAA2022 were confirmed with Sanger sequencing. The clinical phenotypes of all five individuals are summarized in Table 1. 
 
Patient 1 Patient 1 is an eight-year-old female and was reported previously (patient 7 by de Lange et al) [14]. There was oligohydramnios during pregnancy, but no other prenatal complications. Birth weight was 2.4 kg (2nd percentile), length was 49.5 cm (50th percentile), and head circumference was 33.7 cm (50th percentile). Her weight later normalized and she was in the 75th percentile at six years old. She was developmentally delayed and did not talk until twenty-four months. She is now able to speak in two word phrases. She has a limited vocabulary, global developmental delay with an intelligence quotient (IQ) of 56 on the Wechsler Intelligence Scale for Children, and hypotonia.  She began having generalized and absence seizures at 
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twenty-two months and continues to have hundreds of seizures per day. Behaviorally, she is hyperactive, inattentive and anxious, has frequent tantrums, and is unable to dress and feed herself. She has a wide-based unsteady gait and toe walks. Her only dysmorphic features are low-set ears.  Initial brain MRI was normal, but MRI two years later showed generalized atrophy and generalized volume loss. Other medical issues include chronic constipation, use of a gastrostomy tube due to feeding difficulties, anemia and eczema. She has a de novo 14-nucleotide deletion (c.3053_3066del14, p.G1018Dfsx2) in KIAA2022, predicted to produce a truncated protein product of 1018 amino acids.  
 
Patient 2  Patient 2 is an eleven-year-old girl and was reported previously (patient 12 by de Lange et al) [14]. Her mother had an uneventful pregnancy. Birth weight was 3.2 kg (50th percentile) and length was 48.3 cm (25th percentile). She started walking at 15 months, and developmental delays were clearly identified by 20 months. She did not start talking until 4.5 years and currently only speaks in two word phrases. Her IQ is < 60. She began having generalized tonic-clonic seizures at two years old and continues to have between ten and fifteen seizures/day.  Her development regressed with the onset of her seizures. She is unable to dress or feed herself and is continent of urine only during the day. She is hypotonic, has autism spectrum 
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disorder, severe attention deficit hyperactivity disorder, and problems with impulse control. Brain MRIs have been normal. She has a broad-based gait.  She had cardiac rhabdomyomas in the first few years of life and hypopigmented macules with no mutations identified in TSC1 or TSC2. She has a de novo nonsense c.652 C>T, p.R218X mutation in KIAA2022, predicted to produce a truncated 217 amino acid protein product. 
 
Patient 3  Patient 3 is an eleven-year-old girl. Her mother had elevated antibodies to parvovirus during the pregnancy, but no symptoms of parvovirus were demonstrated and weekly prenatal ultrasonography was normal.  Birth weight was 3.5 kg (75th percentile) and length was 49.5 cm (50th percentile). OFC measurements increased from 36.8 cm at 1 month old (50th percentile) to 48.3 cm at 3 years old (50th percentile). She was developmentally delayed, particularly in her limited speech. Currently, she babbles and makes sounds, but has no verbal speech. Other neurological abnormalities include esotropia, hypotonia, hyperactivity and autistic features. She has myoclonic, atonic drop, tonic and tonic-clonic seizures. These seizures are medically refractory and occur an average of forty to sixty times per day, with up to 100 seizures/day.  After she began having seizures, she experienced regression in her vocalization skills. She has limited self-
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care skills, but can undress herself and feed herself with a spoon. She has an ataxic gait, toe walks and has tight heel cords. Her dysmorphic features include a short philtrum, prognathism, low-set hairline, frontal bossing, widely spaced teeth, high-arched palate, and slightly short fingers (Figure 1). Brain MRI was normal. Other medical conditions include gastroesophageal reflux disease, constipation, decreased pain sensitivity and difficulty with chewing and swallowing. She has a de novo frameshift mutation, c.422delA, p.Q141RfsX7 in KIAA2022, predicted to produce a truncated 146 amino acid protein product.   
 
Patient 4  Patient 4 is a six-year-old girl. Her mother had an uneventful pregnancy. Birth weight was 3.3 kg (50th percentile), height was 51 cm (57th percentile) and OFC was 33.5 cm (10th percentile). Her OFC at 4.5 years was 50.5 cm (53rd percentile) and increased to52.2 cm at 5.8 years (81st percentile). She had normal motor milestones but is developmentally delayed. While she began to talk at 8-9 months, she currently only speaks in short three word phrases. She also has esotropia, attention difficulties and tantrums. She began having “shuddering” episodes at four months old, which progressed into myoclonic seizures diagnosed at 1.5 years old. She continues to have daily, uncontrolled seizures. Her gait is normal, but she has poor coordination. Her only dysmorphic feature is inverted nipples. Other medical issues 
This article is protected by copyright. All rights reserved.
11  
include hypotonia, gastroesophageal reflux disease, and easy bruising.  She has a de 
novo duplication, c.625dupC, p.L209PfsX3 mutation in KIAA2022, predicted to produce a truncated 210 amino acid protein product. 
 
Patient 5 Patient 5 is a seven year old girl. Her mother had an uneventful pregnancy. Birth weight was 3.6 kg (75th percentile), length was 52 cm (75th-90th percentile), and OFC was 38.1 cm (50th percentile). She walked without support and said single words at 18 months. She currently speaks in sentences with language skills of a three to four year-old. Her IQ is 48. She also has anxiety and tantrums. Seizures started at two and a half years of age, primarily described as head drops and staring episodes with multiple events per day. Recent electroencephalograms show generalized epilepsy. She has myoclonus and absence-like events that have been medically refractory including failure of the ketogenic diet. She has not experienced significant regression. Her self-care abilities reflect those of a three year-old. She is non-dysmorphic. Other medical conditions include gastroesophageal reflux in infancy, constipation, encopresis and a kidney infection that required hospitalization. She has a de novo nonsense c.C937T, p.R313X mutation in KIAA2022, producing a truncated 312 amino acid product.   
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Discussion  We present phenotypic data from five females with de novo likely gene damaging variants in KIAA2022. All of our patients have intellectual disabilities, medically refractory seizures and impaired language development; two of them have autism spectrum disorders and a third has some autistic features. Three exhibit abnormal or ataxic gait, and a fourth has problems with motor coordination.    Previously described KIAA2022 mutations include microdeletions, duplications, translocations in the non-coding regions of the gene, frameshifts and nonsense mutations and are predicted to act through loss of function (Table 2).   Fifteen of the eighteen previously described patients with KIAA2022 mutations were male. Many of them shared intellectual disabilities, absent or limited language, and autism spectrum disorders. Less consistently observed were dysmorphic facial features (including hypotonic face, narrow forehead, anteverted nostrils, open mouth, and large ears), seizure disorder, and delayed or absent walking. Brain imaging studies in nine patients from six families were normal except for patients 1 and 2 in Table 2. Patient 1 also had a small cerebellar vermis [7-10]. Based on inheritance patterns of these male patients, there are fourteen unaffected female 
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obligate carriers in these families. All were described as clinically normal although they were not evaluated for subtle neurocognitive differences.  The mother of patient 2 expressed normal levels of the KIAA2022 gene unlike her son [7-10].   However, three unrelated female patients with de novo KIAA2022 mutations were recently reported [11-13]. In Table 2, patient 16 had severe intellectual disabilities, autism spectrum disorder, absent language and dysmorphic facial features; patient 17 had mild intellectual disabilities, and patient 18 had severe intellectual disabilities, autistic behavior, limited language, epilepsy, walking difficulties, dysmorphic features, microcephaly and hypotonia. Presumably, an X-linked dominant inheritance pattern with skewed X-inactivation towards the normal allele in the brain could explain why some females with these mutations are affected while others are asymptomatic carriers [11-13]. There likely has been bias of ascertainment in the recognition and reporting of rare variants in KIAA2022 and greater recognition of the role of KIAA2022 in neurodevelopment and behavior should lead to a more complete and less biased description of the full spectrum of phenotypes in females with either inherited or de novo predicted pathogenic variants in KIAA2022.   The variability in phenotype of female carriers could also be partially explained by other additive factors including other interacting genetic factors including possibly tuberous sclerosis in one of our patients. 
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 Compared to previously reported female patients, our patients are younger, and show phenotypic overlap with the more severely affected end of the spectrum. For instance, the female with the p.R628X mutation (patient 17 in Table 2) has a milder phenotype relative to our patients. Our patients and the female with the p.R322X mutation (patient 18 in Table 2) have more severe and refractory epilepsies relative to other reported females. In several neurologic conditions, severity and age at onset of epilepsy is a major morbidity factor, usually related to severity of phenotype, i.e. intelligence quotient or speech [23]. A larger number of patients may allow for establishing similar correlations in this condition.    Our study expands the phenotype of KIAA2022 mutations and demonstrates that females with de novo predicted loss-of-function mutations in KIAA2022 may exhibit similar neurological phenotypes to their male counterparts, including medically refractory seizures and severe intellectual disability.         
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Table 1.  Clinical characteristics of females with de novo likely gene damaging 
mutations in KIAA2022.  WT= weight.  HT=height, OFC=occipital frontal circumference.  GERD= gastroesophageal reflux disease. ID = intellectual disability.  ADD=attention deficit disorder. ADHD=attention deficit hyperactivity disorder. PDD-NOS= pervasive developmental disorder not otherwise specified. Patient 1 2 3 4 5 Mutation g.183982_183995del14 c.3053_3066del14 p.G1018Dfsx2 
g.181581 C>T c.C652T p.R218X g.181351_181351delA c.422delA p.Q141RfsX7 
g.181554_181555dupC c.625dupC p.L209PfsX3 
g.181866 C>T c.C937T p.R313X 
Current age (years) 8 11 11 6 7 Gender Female Female Female Female Female Prenatal issues Oligohydramnios None Elevated parvovirus antibodies None None Congenital anomalies None None None None None Birth WT, HT, OFC  WT = 2.4 kg (2%) HT = 49.5 cm (50%) OFC = 33.7 cm (50%) 
WT = 3.2 kg (50%) HT = 48.3 cm (25%) 
WT = 3.5 kg (75%) HT = 49.5 cm (50%) 
WT = 3.3 kg (50%) HT= 51 cm (57%) 
WT = 3.58kg (75%) HT = 52 cm (75-90%) OFC = 38.1 cm (50%) Current WT, HT At 6 yo  WT = 23.1 kg (75%) HT = 114.3 cm (50%) 
WT = 34.0 kg (25%) HT = 147.3 cm (75%) 
WT = 51.7 kg (90%) HT = 143.4 cm (50%) 
At 5 yo WT = 23.2 kg (95%)  HT = 111.5 cm (75%) OFC = 52.2 cm (81%) 
WT = 36.6kg (95%) HT =130.1cm (80%) 
Gastrointestinal/Growth issues Chronic constipation, gastrostomy tube due to feeding difficulties 
None GERD, constipation GERD GERD, constipation 
Ophthalmologic issues None None Esotropia Esotropia None Developmental delay/ID Yes Yes Yes Yes Yes Age at sitting 6 months 5.5 months “on time” 4 months Not specified 
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Age at walking  12 months 15 months 16 months 15 months 18 months Age at talking 24 months 4.5 years N/A 8-9 months Single words 18 months Current speech abilities Limited language; 2 word phrases, unable to name common objects 
Limited language; 2 word phrases Babbling, some specific sounds Short 3-word phrases Can speak in sentences; language on the CELF is at ~ 4 year level 
Muscle tone Hypotonia Hypotonia Hypotonia Hypotonia Normal Autism Yes Yes Autistic features, but no formal diagnosis 
No No 
ADD/ADHD Hyperactive and inattentive Yes Hyperactive Attention difficulties Not hyperactive, but distracted in classroom environment Full scale IQ 56 <60 Not tested Not tested  48 Notable behaviors Hyperactivity, temper tantrums, anxiety 
Severe ADHD, impulsive control disorder 
Self-injurious behaviors, destructive, stares at objects, licks things, turns in circles 
Tantrums Anxiety, tantrums  
Regression Yes Yes, before onset of seizures Had more vocalization previously; after seizures often would lose and regain skills 
None None 
Seizures Yes – onset at 22 mos Yes – onset at 2 years Yes Yes – first at 4 mos Yes Seizure type / EEG results Generalized epilepsy; absence seizures (intractable) 
Generalized, tonic clonic seizures (intractable) 
Myoclonic, atonic drop seizures, absence, tonic, tonic-clonic (intractable) 
Myoclonic epilepsy - diagnosed at age 1.5 yo; myoclonic astatic 
Staring episodes with clonic jerks; generalized epilepsy (intractable) Seizure frequency Hundreds per day 10-15 per day 40-60 per day Daily  Daily  
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Ataxia Wide-based unsteady gait with toe walking 
Broad-based gait Ataxic gait, toe walking Problems with coordination None Other neurological or neuromuscular disorder(s) 
None None Tight heel cords None None 
Self-care abilities None Unable to dress or feed herself; can urinate in toilet during the day; wears diaper at night 
Emerging skills: can undress self, feeds self with spoon 
Not provided Consistent with that of a 3 year old 
Brain MRI/CT results Generalized atrophy on MRI 2 normal MRIs Normal MRI Normal MRI Normal MRI Dysmorphic features Low set ears None Short philtrum, prognathism, low-set hairline, frontal bossing, widely spaced teeth, highly arched palate, slightly short fingers 
Inverted nipples None 
Additional medical problems Anemia, eczema Cardiac rhabdomyomas found in first few years of life with negative TSC 
1 and TSC2 gene testing.  No brain tubers or renal lesions. Hypopigmented macules. 
Decreased pain sensitivity, chewing and swallowing difficulties 
Bruises easily Significant kidney infection in past 
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Table 2: Clinical characteristics of previously described patients with mutations in 
KIAA2022.  GERD=gastroesophageal reflux disease; NA= data not available 
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1 
Inherited; Translocation (Intron 1) M 13 Severe-Profound  X X None Dysmorphic X 
MRI: moderate brain atrophy, small cerebellar vermis, thick calvarium 
2 
Inherited; Translocation (Intron 1) M 20 Severe-Profound X X X Generalized Dysmorphic X CT: frontal cortical atrophy 
3 
Inherited; Duplication (p.S1200YfsX5) M 6 Severe-Profound X X  Flexor spasms Dysmorphic X NA 
4 
Inherited; Duplication (p.S1200YfsX5) M 4 Severe-Profound X X X Flexor spasms Dysmorphic X NA 
5 
Inherited; 70kb Microdeletion (Exon 1) M 8 Mild X X  None Dysmorphic X MRI: normal @ 9yo 
6 
Inherited; Deletion (p.R62EfsX22) M 14 Moderate-Severe  X  None Dysmorphic X MRI: normal 
7 
Inherited; Deletion (p.R62EfsX22) M 10 Moderate-Severe X X  Lennox-Gastaut Dysmorphic X MRI: normal 
8 
Inherited; Deletion (p.R62EfsX22) M 40 Moderate  X  Generalized Dysmorphic NA NA 
9 
Inherited; Duplication (Xq13.3: whole gene + intergenic sequences) 
M NA Moderate X   None Normal NA MRI: normal 
10 
Inherited; Duplication (Xq13.3: whole gene + intergenic sequences) 
M NA Severe X   Generalized paroxysmal seizures on EEG Normal NA MRI: normal 
11 
Inherited; Duplication (Xq13.3: whole gene + intergenic sequences) 
M NA NA  X  None NA NA NA 
12 
Inherited; Duplication (Xq13.3: whole M NA X    NA NA NA NA 
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gene + intergenic sequences) 
13 
Inherited; Duplication (Xq13.3: whole gene + intergenic sequences) 
M NA X    NA NA NA NA 
14 
De novo; Nonsense (p.Q705X) M 3 Severe X X X None Dysmorphic X MRI: normal 
15 
De novo; Nonsense (p.R322X) M 5 Severe X X X None Dysmorphic X MRI: normal 
16 
De novo; Translocation (Intron 1) F 26 Severe X X  None Dysmorphic NA NA 
17 
De novo; Nonsense (p.R628X) F 13 Mild    None Normal NA MRI: normal 
18 
De novo; Nonsense (p.R322X) F 17 Severe X X X 
Absence, atonic drop, tonic & generalized seizures Dysmorphic X Normal 
19 
De novo; Nonsense (p.K1396fs) F 26 X X  X Generalized tonic-clonic, myoclonic Normal  Normal 
20 
De novo, Nonsense (p.C146*) F 9 X X  X 
Generalized and focal; tonic-clonic, myoclonic, absence, atonic 
Dysmorphic X Normal 
21 
De novo; Nonsense (p.G681fs) F 25 X   X 
Generalized  tonic-clonic, myoclonic, absence, atonic Normal  Normal 
22 
De novo; Nonsense (p.R322*) F 11 X +   
Generalized, and focal myoclonic, tonic atonic Normal  Normal 
23 
De novo; Nonsense (p.K734Sfs*24) F 36 X    
Generalized tonic-clonic, myoclonic, absence Normal  Normal 
24 
De novo; Nonsense (p.R481*) F 2 X  X X  Dysmorphic X Normal 
25 
De novo; Deletion  (Exon 1) F 18 X X X X Focal clonic Normal  Normal 
26 
De novo; Nonsense (p.R528Qfs*4) F 5 X  X X 
Generalized myoclonic, absence, tonic-clonic, atonic Normal  Normal 
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27 
De novo; Nonsense (p.R628*) F 2 X  X X  Normal X Normal 
28 
De novo; Nonsense (p.A909Pfs*13) F 53     Generalized, absence Normal  N/A 
29 
De novo; Nonsense (p.Q318*) F 51 X  X X 
Generalized tonic-clonic,  myoclonic, atonic, tonic-clonic, Dysmorphic  Normal 
30 
De novo; Nonsense (p.K1199Nfs) F 8 X  X X 
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Legends: 
 
Figure 1: Facial characteristics of Patient 3 including a short philtrum, prognathism, low-set hairline, frontal bossing, and widely spaced teeth 
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